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Subacute polyradiculoneuritis revealing syphilis in an HIV-negative
man
Although the incidence of neurosyphilis has dramatically
decreased since the introduction of antibiotics, it is still preva-
lent, particularly in the HIV-infected population [1]. Its most
common clinical presentation includes tabes dorsalis and general
paresis [2,3]. In contrast, polyradiculoneuritis has seldom been
reported during syphilis [4–6]. We thus report a case of subacute
polyradiculoneuritis caused by Treponema pallidum in an HIV-
negative man and review the other cases.
A Niger-native 40-year-old man presented in June 1991
with pain in the legs, which suddenly disappeared. In December
1991, leg weakness and heaviness reappeared, creating walking
difficulties. In January 1992, he suddenly presented a tetra-
paresia with absence of deep tendon reflexes but no sensory
deficit, which justified his admission at the hospital in Niamey
(Niger). Three weeks later, he was referred to Paris (France) in
order for the investigations to be completed. Physical exam-
ination revealed good general condition, apyrexia and no extra-
neurologic signs. There was a discrete bilateral muscular leg
weakness predominating proximally. Deep tendon reflexes
were reduced at the knees and absent at the ankles. There
were no pyramidal signs and no incontinence. Sphincter tone,
vibration, joint position and pinprick sensation were normal.
However, there was a cutaneous hyperesthesia on the legs.
There was a bilateral Argyll Robertson’s sign. Cerebrospinal
fluid (CSF) examination showed less than 1 cell/mL, protein
level 1.1 g/L with normal glucose, and increased gamma-
globulin (IgG = 228 mg/L, normal 7–61 mg/L) levels. The
Venereal Disease Research Laboratory (VDRL) test was nega-
tive in the CSF, but CSF T. pallidum hemagglutination assay
(TPHA) was positive (1/80) in the CSF, and TPHA index
(TPHA CSF/serum  1000  albumin serum/CSF) was
793. Serum VDRL was reactive in a 1 : 32 dilution, serum
TPHA in a 1 : 640 dilution, and serum FTA-abs in a 1 : 25 600
dilution. The search for HIV-1 and HIV-2 antibodies was
negative in the serum.
The patient received 25 million units of intravenous aqueous
crystalline penicillin G daily for 3 weeks. Muscular leg weakness
disappeared and his clinical condition dramatically improved.
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Unfortunately, no control of the CSF was obtained because the
patient left Paris and returned to Niger.
This report documents subacute polyradiculoneuritis due to
confirmed syphilis in a non-HIV-infected African patient. He
presented with symptoms mimicking Guillain–Barre´’s syn-
drome in association with bilateral Argyll Robertson’s sign,
hypergammaglobulinemia in the CSF and positivity of both
TPHA and the TPHA index 100 in the CSF [7].
The clinical presentation of neurosyphilis has changed.
Indeed, classical forms such as general paresis and tabes dorsalis
have decreased, while meningovascular and meningo-
encephalitis forms have increased in frequency, especially in
HIV-infected patients [7,8]. In contrast, syphilitic poly-
radiculoneuropathy has rarely been reported (Table 1). Lanska
et al [4] described an HIV-infected man in whom syphilitic
polyradiculopathy occurred 4 months after the rash of secondary
syphilis. Two other cases have been recently described in HIV-
negative patients. In one, polyradiculopathy occurred simul-
taneously with a maculopapular rash [5]. In the other, a tertiary
or late symptomatic neurosyphilis presented as a motor poly-
radiculoneuropathy without any previous skin rash [6]. All these
three cases recovered after penicillin therapy.
In conclusion, infection due to T. pallidum is a curable
cause of polyradiculoneuritis which may occur in HIV-negative
patients; appropriate tests in both serum and CSF should be
performed in patients with polyradiculoneuritis.
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Revision of quality control limits for cefotaxime disk susceptibility
tests
In the past few years, we have experienced difficulty when
cefotaxime disks were tested against the control strain of Strep-
tococcus pneumoniae (ATCC 49619), because zones were fre-
quently too large. As part of a recent multilaboratory study, we
were able to re-evaluate the quality control ranges for cefot-
axime disks tested against five different control strains, including
S. pneumoniae ATCC 49619.
The 10 participating laboratories are identified in the
Acknowledgments. Each participant was provided with agar
plates containing Mueller–Hinton agars from three different
manufacturers (Acumedia lot 9808187, Difco lot 107846JG and
BDMS lot 10 D1GE). For testing the pneumococcus, 5% sheep
blood was added to the agar media. For testing Haemophilus
influenzae, the Mueller–Hinton agars were prepared as Haemo-
philus Test Medium [1]. The participants were also provided
with 30-mg cefotaxime disks from two manufacturers (Remel
lot 30–836 5502 and BDMS lot 711558). Either cefaclor
(BDMS lot 1006610611) or cefixime (Remel lot 30–134 5508)
disks were used for internal control purposes. If zones around
the control disks were not within the established limits, the tests
were to be repeated, and if they remained out of control,
cefotaxime zones produced on that test plate were excluded
from our analysis. Because of space limitations, a Pseudomonas-
active control disk could not be tested against Pseudomonas
aeruginosa ATCC 27853, but only two of 600 cefotaxime zones
were outside the current control range of 18–22 mm [2] and
no changes are proposed.
Each participant independently tested all five control strains
on 10 different test days, following the disk test procedure
of the National Committee for Clinical Laboratory Standards
(NCCLS) [1]. On each test day, one inoculum suspension was
prepared for each control strain and the turbidity was adjusted
to match that of a McFarland 0.5 turbidity standard. Then,
three agar plates were inoculated, each from a different lot of
Mueller–Hinton agar. Each plate received two 30-mg cefot-
axime disks and one control disk (5 mg of cefixime or 30 mg of
cefaclor). The test plates were incubated for 18–20 h at 35 °C
in ambient air or for 20–24 h in 5–10% CO2 for the S. pneu-
moniae and H. influenzae control strains [1]. In this way, all 10
laboratories reported 600 cefotaxime zone diameters for each
control strain. Unsatisfactory control disk results excluded 0.3–
3.3% of those determinations. The excluded cefotaxime zones
were all within the current or proposed control ranges for
cefotaxime disk tests.
The results of this exercise are summarized in Table 1. The
current control ranges for 30-mg cefotaxime disk tests [2] against
